• 19
  • 1
  • 收藏

U.S. FDA declines emergency use approval for Humanigen's COVID-19 drug

Reuters2021-09-09

Sept 9 (Reuters) - The U.S. Food and Drug Administration declined Humanigen Inc's request for emergency use authorization of its lenzilumab drug to treat newly hospitalized COVID-19 patients, the company said on Thursday.

"In its letter, FDA stated that it was unable to conclude that the known and potential benefits of lenzilumab outweigh the known and potential risks of its use as a treatment for COVID-19," the company said in a statement.

Humanigen expects an ongoing study to provide additional safety and efficacy data to support its new EUA request.

The company filed its application with the FDA for emergency use of the drug in May, citing late-stage trial data.

Humanigen also started the process of UK authorization for the drug in June through a rolling review submission.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

举报

评论1

  • RyanYe
    ·2021-09-09
    中奖了
    回复
    举报
 
 
 
 

热议股票

 
 
 
 
 

7x24